

Heidrun Potschka

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7901887/heidrun-potschka-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

136
papers

6,725
citations

41
h-index

80
g-index

145
ext. papers

7,769
ext. citations

4.9
avg, IF

6.16
L-index

#	Paper	IF	Citations
136	Development of behavioral patterns in young C57BL/6J mice: a home cage-based study.. <i>Scientific Reports</i> , 2022 , 12, 2550	4.9	1
135	The impact of tethered recording techniques on activity and sleep patterns in rats.. <i>Scientific Reports</i> , 2022 , 12, 3179	4.9	0
134	Cyclooxygenase-2 Inhibition as an Add-On Strategy in Drug Resistant Epilepsy-A Canine Translational Study.. <i>Frontiers in Veterinary Science</i> , 2022 , 9, 864293	3.1	0
133	Targeted Molecular Strategies for Genetic Neurodevelopmental Disorders: Emerging Lessons from Dravet Syndrome.. <i>Neuroscientist</i> , 2022 , 10738584221088244	7.6	
132	The impact of Scn1a deficiency and ketogenic diet on the intestinal microbiome: A study in a genetic Dravet mouse model. <i>Epilepsy Research</i> , 2021 , 178, 106826	3	3
131	Introduction to the EQIPD quality system. <i>ELife</i> , 2021 , 10,	8.9	11
130	Hippocampal and Septal 5-HT Receptor Expression in Two Rat Models of Temporal Lobe Epilepsy. <i>Neuroscience</i> , 2021 , 465, 219-230	3.9	
129	Metabolomic signature of the Dravet syndrome: A genetic mouse model study. <i>Epilepsia</i> , 2021 , 62, 2000-2014	6.4	4
128	Procedures for Electrical and Chemical Kindling Models in Rats and Mice. <i>Neuromethods</i> , 2021 , 103-119	0.4	
127	Toward evidence-based severity assessment in mouse models with repeated seizures: I. Electrical kindling. <i>Epilepsy and Behavior</i> , 2021 , 115, 107689	3.2	3
126	The role of new medical treatments for the management of developmental and epileptic encephalopathies: Novel concepts and results. <i>Epilepsia</i> , 2021 , 62, 857-873	6.4	5
125	Management of COVID-19 in patients with seizures: Mechanisms of action of potential COVID-19 drug treatments and consideration for potential drug-drug interactions with anti-seizure medications. <i>Epilepsy Research</i> , 2021 , 174, 106675	3	5
124	Proteomic signature of the Dravet syndrome in the genetic Scn1a-A1783V mouse model. <i>Neurobiology of Disease</i> , 2021 , 157, 105423	7.5	4
123	Seizures in dogs under primary veterinary care in the United Kingdom: Etiology, diagnostic testing, and clinical management. <i>Journal of Veterinary Internal Medicine</i> , 2020 , 34, 2525-2535	3.1	3
122	Design of composite measure schemes for comparative severity assessment in animal-based neuroscience research: A case study focussed on rat epilepsy models. <i>PLoS ONE</i> , 2020 , 15, e0230141	3.7	5
121	Drug Resistance in Epilepsy: Clinical Impact, Potential Mechanisms, and New Innovative Treatment Options. <i>Pharmacological Reviews</i> , 2020 , 72, 606-638	22.5	121
120	Molecular alterations of the TLR4-signaling cascade in canine epilepsy. <i>BMC Veterinary Research</i> , 2020 , 16, 18	2.7	3

119	Systematic review of guidelines for internal validity in the design, conduct and analysis of preclinical biomedical experiments involving laboratory animals.. <i>BMJ Open Science</i> , 2020 , 4, e100046	4.6	16
118	[F]MPPF and [F]FDG PET imaging in rats: impact of transport and restraint stress. <i>EJNMMI Research</i> , 2020 , 10, 112	3.6	2
117	A safe bet? Inter-laboratory variability in behaviour-based severity assessment. <i>Laboratory Animals</i> , 2020 , 54, 73-82	2.6	7
116	Semi-automated generation of pictures for the Mouse Grimace Scale: A multi-laboratory analysis (Part 2). <i>Laboratory Animals</i> , 2020 , 54, 92-98	2.6	6
115	Regulation of Alzheimer's disease-associated proteins during epileptogenesis. <i>Neuroscience</i> , 2020 , 424, 102-120	3.9	3
114	Defining body-weight reduction as a humane endpoint: a critical appraisal. <i>Laboratory Animals</i> , 2020 , 54, 99-110	2.6	20
113	Where are we heading? Challenges in evidence-based severity assessment. <i>Laboratory Animals</i> , 2020 , 54, 50-62	2.6	8
112	Profiling the Expression of Endoplasmic Reticulum Stress Associated Heat Shock Proteins in Animal Epilepsy Models. <i>Neuroscience</i> , 2020 , 429, 156-172	3.9	3
111	Disruption of the sodium-dependent citrate transporter SLC13A5 in mice causes alterations in brain citrate levels and neuronal network excitability in the hippocampus. <i>Neurobiology of Disease</i> , 2020 , 143, 105018	7.5	9
110	Imepitoin for treatment of idiopathic head tremor syndrome in dogs: A randomized, blinded, placebo-controlled study. <i>Journal of Veterinary Internal Medicine</i> , 2020 , 34, 2571-2581	3.1	1
109	COVID-19 and seizures: Is there a link?. <i>Epilepsia</i> , 2020 , 61, 1840-1853	6.4	36
108	Nest-building performance in rats: impact of vendor, experience, and sex. <i>Laboratory Animals</i> , 2020 , 54, 17-25	2.6	8
107	Exploratory EEG studies for the assessment of neurological liabilities in conscious dogs in early drug development. <i>Journal of Pharmacological and Toxicological Methods</i> , 2019 , 98, 106581	1.7	0
106	2017 WONOEP appraisal: Studying epilepsy as a network disease using systems biology approaches. <i>Epilepsia</i> , 2019 , 60, 1045-1053	6.4	5
105	Perampanel: Does it have broad-spectrum potential?. <i>Epilepsia</i> , 2019 , 60 Suppl 1, 22-36	6.4	23
104	Epileptogenesis-Associated Alterations of Heat Shock Protein 70 in a Rat Post-Status Epilepticus Model. <i>Neuroscience</i> , 2019 , 415, 44-58	3.9	7
103	Toward evidence-based severity assessment in rat models with repeated seizures: III. Electrical post-status epilepticus model. <i>Epilepsia</i> , 2019 , 60, 1539-1551	6.4	11
102	Toward evidence-based severity assessment in rat models with repeated seizures: II. Chemical post-status epilepticus model. <i>Epilepsia</i> , 2019 , 60, 2114-2127	6.4	8

101	Genetic and Pharmacological Targeting of Heat Shock Protein 70 in the Mouse Amygdala-Kindling Model. <i>ACS Chemical Neuroscience</i> , 2019 , 10, 1434-1444	5.7	6
100	Impact of repeated kindled seizures on heart rate rhythms, heart rate variability, and locomotor activity in rats. <i>Epilepsy and Behavior</i> , 2019 , 92, 36-44	3.2	9
99	Toward evidence-based severity assessment in rat models with repeated seizures: I. Electrical kindling. <i>Epilepsia</i> , 2018 , 59, 765-777	6.4	20
98	Proteomic profiling of epileptogenesis in a rat model: Focus on cell stress, extracellular matrix and angiogenesis. <i>Neurobiology of Disease</i> , 2018 , 112, 119-135	7.5	17
97	Seizure occurrence in dogs under primary veterinary care in the UK: prevalence and risk factors. <i>Journal of Veterinary Internal Medicine</i> , 2018 , 32, 1665-1676	3.1	22
96	Imaging biomarkers of behavioral impairments: A pilot micro-positron emission tomographic study in a rat electrical post-status epilepticus model. <i>Epilepsia</i> , 2018 , 59, 2194-2205	6.4	12
95	Imaging correlates of behavioral impairments: An experimental PET study in the rat pilocarpine epilepsy model. <i>Neurobiology of Disease</i> , 2018 , 118, 9-21	7.5	15
94	Genetic Modulation of HSPA1A Accelerates Kindling Progression and Exerts Pro-convulsant Effects. <i>Neuroscience</i> , 2018 , 386, 108-120	3.9	5
93	Identification of brain regions predicting epileptogenesis by serial [F]GE-180 positron emission tomography imaging of neuroinflammation in a rat model of temporal lobe epilepsy. <i>NeuroImage: Clinical</i> , 2017 , 15, 35-44	5.3	20
92	A systems level analysis of epileptogenesis-associated proteome alterations. <i>Neurobiology of Disease</i> , 2017 , 105, 164-178	7.5	18
91	Naturally Occurring Epilepsy and Status Epilepticus in Dogs 2017 , 387-398		
90	Neuroinflammation imaging markers for epileptogenesis. <i>Epilepsia</i> , 2017 , 58 Suppl 3, 11-19	6.4	30
89	WONOE appraisal: Imaging biomarkers in epilepsy. <i>Epilepsia</i> , 2017 , 58, 315-330	6.4	21
88	miRNA-187-3p-Mediated Regulation of the KCNK10/TREK-2 Potassium Channel in a Rat Epilepsy Model. <i>ACS Chemical Neuroscience</i> , 2016 , 7, 1585-1594	5.7	12
87	Proteomic profiling of epileptogenesis in a rat model: Focus on inflammation. <i>Brain, Behavior, and Immunity</i> , 2016 , 53, 138-158	16.6	46
86	Minocycline fails to exert antiepileptogenic effects in a rat status epilepticus model. <i>European Journal of Pharmacology</i> , 2016 , 771, 29-39	5.3	14
85	Synergism of perampanel and zonisamide in the rat amygdala kindling model of temporal lobe epilepsy. <i>Epilepsia</i> , 2016 , 57, 638-47	6.4	18
84	Glutamate-Mediated Down-Regulation of the Multidrug-Resistance Protein BCRP/ABCG2 in Porcine and Human Brain Capillaries. <i>Molecular Pharmaceutics</i> , 2015 , 12, 2049-60	5.6	18

83	International Veterinary Epilepsy Task Force consensus proposal: medical treatment of canine epilepsy in Europe. <i>BMC Veterinary Research</i> , 2015 , 11, 176	2.7	67
82	International veterinary epilepsy task force consensus report on epilepsy definition, classification and terminology in companion animals. <i>BMC Veterinary Research</i> , 2015 , 11, 182	2.7	149
81	International veterinary epilepsy task force consensus proposal: outcome of therapeutic interventions in canine and feline epilepsy. <i>BMC Veterinary Research</i> , 2015 , 11, 177	2.7	37
80	International veterinary epilepsy task force consensus proposal: diagnostic approach to epilepsy in dogs. <i>BMC Veterinary Research</i> , 2015 , 11, 148	2.7	116
79	Microglial ROS production in an electrical rat post-status epilepticus model of epileptogenesis. <i>Neuroscience Letters</i> , 2015 , 599, 146-51	3.3	2
78	Expression regulation and targeting of the peroxisome proliferator-activated receptor β following electrically-induced status epilepticus. <i>Neuroscience Letters</i> , 2015 , 604, 151-6	3.3	4
77	N-acetyl-L-leucine accelerates vestibular compensation after unilateral labyrinthectomy by action in the cerebellum and thalamus. <i>PLoS ONE</i> , 2015 , 10, e0120891	3.7	43
76	International veterinary epilepsy task force recommendations for systematic sampling and processing of brains from epileptic dogs and cats. <i>BMC Veterinary Research</i> , 2015 , 11, 216	2.7	17
75	International Veterinary Epilepsy Task Force recommendations for a veterinary epilepsy-specific MRI protocol. <i>BMC Veterinary Research</i> , 2015 , 11, 194	2.7	30
74	Glutamate-mediated upregulation of the multidrug resistance protein 2 in porcine and human brain capillaries. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2015 , 352, 368-78	4.7	20
73	Impact of the neural cell adhesion molecule-derived peptide FGL on seizure progression and cellular alterations in the mouse kindling model. <i>ACS Chemical Neuroscience</i> , 2014 , 5, 185-93	5.7	3
72	Targeting of microglial KCa3.1 channels by TRAM-34 exacerbates hippocampal neurodegeneration and does not affect ictogenesis and epileptogenesis in chronic temporal lobe epilepsy models. <i>European Journal of Pharmacology</i> , 2014 , 740, 72-80	5.3	15
71	The mixed blessing of treating symptoms in acute vestibular failure--evidence from a 4-aminopyridine experiment. <i>Experimental Neurology</i> , 2014 , 261, 638-45	5.7	23
70	Effect of eslicarbazepine acetate in the corneal kindling progression and the amygdala kindling model of temporal lobe epilepsy. <i>Epilepsy Research</i> , 2014 , 108, 212-22	3	17
69	(R)-[11C]PK11195 brain uptake as a biomarker of inflammation and antiepileptic drug resistance: evaluation in a rat epilepsy model. <i>Neuropharmacology</i> , 2014 , 85, 104-12	5.5	34
68	Pre-treatment with the NMDA receptor glycine-binding site antagonist L-701,324 improves pharmacosensitivity in a mouse kindling model. <i>Epilepsy Research</i> , 2014 , 108, 634-43	3	7
67	CNS transporters and drug delivery in epilepsy. <i>Current Pharmaceutical Design</i> , 2014 , 20, 1534-42	3.3	15
66	[11C]quinidine and [11C]laniquidar PET imaging in a chronic rodent epilepsy model: impact of epilepsy and drug-responsiveness. <i>Nuclear Medicine and Biology</i> , 2013 , 40, 764-75	2.1	20

65	The novel antiepileptic drug imepitoin compares favourably to other GABA-mimetic drugs in a seizure threshold model in mice and dogs. <i>Pharmacological Research</i> , 2013 , 77, 39-46	10.2	22
64	The CNTF-derived peptide mimetic Cintrofin attenuates spatial-learning deficits in a rat post-status epilepticus model. <i>Neuroscience Letters</i> , 2013 , 556, 170-5	3.3	3
63	Canine epilepsy as a translational model?. <i>Epilepsia</i> , 2013 , 54, 571-9	6.4	72
62	Dynamic regulation of P-glycoprotein in human brain capillaries. <i>Molecular Pharmaceutics</i> , 2013 , 10, 3333-41	3.6	33
61	Lacosamide treatment following status epilepticus attenuates neuronal cell loss and alterations in hippocampal neurogenesis in a rat electrical status epilepticus model. <i>Epilepsia</i> , 2013 , 54, 1176-85	6.4	31
60	Animal and human data: where are our concepts for drug-resistant epilepsy going?. <i>Epilepsia</i> , 2013 , 54 Suppl 2, 29-32	6.4	10
59	Modulating P-glycoprotein Regulation as a Therapeutic Strategy for Pharmacoresistant Epilepsy 2013 , 225-232		
58	Finding a better drug for epilepsy: antiepileptogenesis targets. <i>Epilepsia</i> , 2012 , 53, 1868-76	6.4	68
57	Pharmacoresistance. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2012 , 108, 741-57	3	15
56	Long-term genetic fate mapping of adult generated neurons in a mouse temporal lobe epilepsy model. <i>Neurobiology of Disease</i> , 2012 , 48, 454-63	7.5	10
55	Animal models of drug-resistant epilepsy. <i>Epileptic Disorders</i> , 2012 , 14, 226-34	1.9	35
54	Role of CNS efflux drug transporters in antiepileptic drug delivery: overcoming CNS efflux drug transport. <i>Advanced Drug Delivery Reviews</i> , 2012 , 64, 943-52	18.5	60
53	Impact of the NCAM derived mimetic peptide plannexin on the acute cellular consequences of a status epilepticus. <i>Neuroscience Letters</i> , 2011 , 501, 173-8	3.3	2
52	Impact of seizure activity on free extracellular phenytoin concentrations in amygdala-kindled rats. <i>Neuropharmacology</i> , 2011 , 61, 909-17	5.5	13
51	Add-on treatment with verapamil in pharmacoresistant canine epilepsy. <i>Epilepsia</i> , 2011 , 52, 284-91	6.4	18
50	Targeting the endocannabinoid system in the amygdala kindling model of temporal lobe epilepsy in mice. <i>Epilepsia</i> , 2011 , 52, e62-5	6.4	32
49	The erythropoietin-derived peptide mimetic pHBSP affects cellular and cognitive consequences in a rat post-status epilepticus model. <i>Epilepsia</i> , 2011 , 52, 2333-43	6.4	18
48	Impact of the erythropoietin-derived peptide mimetic Epotris on the histopathological consequences of status epilepticus. <i>Epilepsy Research</i> , 2011 , 96, 241-9	3	15

47	Modulation of neurogenesis by targeted hippocampal irradiation fails to affect kindling progression. <i>Hippocampus</i> , 2011 , 21, 866-76	3.5	26
46	COX-2 inhibition controls P-glycoprotein expression and promotes brain delivery of phenytoin in chronic epileptic rats. <i>Neuropharmacology</i> , 2010 , 58, 404-12	5.5	101
45	Uptake and binding of the serotonin 5-HT _{1A} antagonist [18F]-MPPF in brain of rats: effects of the novel P-glycoprotein inhibitor tariquidar. <i>NeuroImage</i> , 2010 , 49, 1406-15	7.9	41
44	Targeting the brain--surmounting or bypassing the blood-brain barrier. <i>Handbook of Experimental Pharmacology</i> , 2010 , 411-31	3.2	32
43	Transporter hypothesis of drug-resistant epilepsy: challenges for pharmacogenetic approaches. <i>Pharmacogenomics</i> , 2010 , 11, 1427-38	2.6	32
42	Polysialic acid affects pathophysiological consequences of status epilepticus. <i>NeuroReport</i> , 2010 , 21, 549-53	1.7	4
41	Targeting regulation of ABC efflux transporters in brain diseases: a novel therapeutic approach. <i>Pharmacology & Therapeutics</i> , 2010 , 125, 118-27	13.9	44
40	Targeting the prostaglandin E ₂ EP ₁ receptor and cyclooxygenase-2 in the amygdala kindling model in mice. <i>Epilepsy Research</i> , 2010 , 91, 57-65	3	20
39	Modulating P-glycoprotein regulation: future perspectives for pharmaco-resistant epilepsies?. <i>Epilepsia</i> , 2010 , 51, 1333-47	6.4	79
38	Imaging of P-glycoprotein-mediated pharmaco-resistance in the hippocampus: proof-of-concept in a chronic rat model of temporal lobe epilepsy. <i>Epilepsia</i> , 2010 , 51, 1780-90	6.4	39
37	Drug resistance in epilepsy. <i>Epilepsia</i> , 2010 , 51, 91-91	6.4	6
36	Targeting prostaglandin E ₂ EP ₁ receptors prevents seizure-associated P-glycoprotein up-regulation. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2009 , 330, 939-47	4.7	79
35	Cellular localization of Y-box binding protein 1 in brain tissue of rats, macaques, and humans. <i>BMC Neuroscience</i> , 2009 , 10, 28	3.2	16
34	Prevention of seizure-induced up-regulation of endothelial P-glycoprotein by COX-2 inhibition. <i>Neuropharmacology</i> , 2009 , 56, 849-55	5.5	100
33	In vivo down-regulation of mouse brain capillary P-glycoprotein: a preliminary investigation. <i>Neuroscience Letters</i> , 2009 , 464, 47-51	3.3	13
32	Brain penetration and anticonvulsant efficacy of intranasal phenobarbital in rats. <i>Epilepsia</i> , 2008 , 49, 1142-50	6.4	10
31	Targeting epileptogenesis-associated induction of neurogenesis by enzymatic depolysialylation of NCAM counteracts spatial learning dysfunction but fails to impact epilepsy development. <i>Journal of Neurochemistry</i> , 2008 , 105, 389-400	6	57
30	Effect of aging on neurogenesis in the canine brain. <i>Aging Cell</i> , 2008 , 7, 368-74	9.9	53

29	Seizure-induced up-regulation of P-glycoprotein at the blood-brain barrier through glutamate and cyclooxygenase-2 signaling. <i>Molecular Pharmacology</i> , 2008 , 73, 1444-53	4.3	191
28	Impact of the PSA-NCAM system on pathophysiology in a chronic rodent model of temporal lobe epilepsy. <i>Neurobiology of Disease</i> , 2007 , 27, 54-66	7.5	44
27	Valproic acid is not a substrate for P-glycoprotein or multidrug resistance proteins 1 and 2 in a number of in vitro and in vivo transport assays. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2007 , 320, 331-43	4.7	138
26	Newborn neurons with hilar basal dendrites hallmark epileptogenic networks. <i>NeuroReport</i> , 2007 , 18, 585-9	1.7	7
25	Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein. <i>Neuropharmacology</i> , 2007 , 52, 333-46	5.5	198
24	Prophylactic treatment with levetiracetam after status epilepticus: lack of effect on epileptogenesis, neuronal damage, and behavioral alterations in rats. <i>Neuropharmacology</i> , 2007 , 53, 207-21	5.5	64
23	Neurogenesis in the adult rat piriform cortex. <i>NeuroReport</i> , 2006 , 17, 571-4	1.7	74
22	Effects of the novel antiepileptic drug lacosamide on the development of amygdala kindling in rats. <i>Epilepsia</i> , 2006 , 47, 1803-9	6.4	54
21	Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases. <i>Progress in Neurobiology</i> , 2005 , 76, 22-76	10.9	481
20	Blood-brain barrier active efflux transporters: ATP-binding cassette gene family. <i>NeuroRx</i> , 2005 , 2, 86-98		563
19	Drug resistance in brain diseases and the role of drug efflux transporters. <i>Nature Reviews Neuroscience</i> , 2005 , 6, 591-602	13.5	695
18	Immunohistochemical localization of P-glycoprotein in rat brain and detection of its increased expression by seizures are sensitive to fixation and staining variables. <i>Journal of Histochemistry and Cytochemistry</i> , 2005 , 53, 517-31	3.4	99
17	Anticonvulsant efficacy of the low-affinity partial benzodiazepine receptor agonist ELB 138 in a dog seizure model and in epileptic dogs with spontaneously recurrent seizures. <i>Epilepsia</i> , 2004 , 45, 1228-39	6.4	46
16	Increased expression of the multidrug transporter P-glycoprotein in limbic brain regions after amygdala-kindled seizures in rats. <i>Epilepsy Research</i> , 2004 , 58, 67-79	3	78
15	Pharmacoresistance and expression of multidrug transporter P-glycoprotein in kindled rats. <i>NeuroReport</i> , 2004 , 15, 1657-61	1.7	61
14	Epileptogenesis and neuropathology after different types of status epilepticus induced by prolonged electrical stimulation of the basolateral amygdala in rats. <i>Epilepsy Research</i> , 2003 , 55, 83-103 ³		114
13	Multidrug resistance protein MRP2 contributes to blood-brain barrier function and restricts antiepileptic drug activity. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2003 , 306, 124-31	4.7	203
12	Lack of effects of prolonged treatment with phenobarbital or phenytoin on the expression of P-glycoprotein in various rat brain regions. <i>European Journal of Pharmacology</i> , 2002 , 451, 149-55	5.3	37

11	Effects of the novel antiepileptic drug levetiracetam on spontaneous recurrent seizures in the rat pilocarpine model of temporal lobe epilepsy. <i>Epilepsia</i> , 2002 , 43, 350-7	6.4	122
10	Expression of the multidrug transporter P-glycoprotein in brain capillary endothelial cells and brain parenchyma of amygdala-kindled rats. <i>Epilepsia</i> , 2002 , 43, 675-84	6.4	55
9	Transient increase of P-glycoprotein expression in endothelium and parenchyma of limbic brain regions in the kainate model of temporal lobe epilepsy. <i>Epilepsy Research</i> , 2002 , 51, 257-68	3	93
8	A comparison of extracellular levels of phenytoin in amygdala and hippocampus of kindled and non-kindled rats. <i>NeuroReport</i> , 2002 , 13, 167-71	1.7	27
7	P-Glycoprotein-mediated efflux of phenobarbital, lamotrigine, and felbamate at the blood-brain barrier: evidence from microdialysis experiments in rats. <i>Neuroscience Letters</i> , 2002 , 327, 173-6	3.3	204
6	In vivo evidence for P-glycoprotein-mediated transport of phenytoin at the blood-brain barrier of rats. <i>Epilepsia</i> , 2001 , 42, 1231-40	6.4	168
5	Repeated low-dose treatment of rats with pilocarpine: low mortality but high proportion of rats developing epilepsy. <i>Epilepsy Research</i> , 2001 , 46, 111-9	3	150
4	P-glycoprotein and multidrug resistance-associated protein are involved in the regulation of extracellular levels of the major antiepileptic drug carbamazepine in the brain. <i>NeuroReport</i> , 2001 , 12, 3557-60	1.7	183
3	Anticonvulsant and proconvulsant effects of tramadol, its enantiomers and its M1 metabolite in the rat kindling model of epilepsy. <i>British Journal of Pharmacology</i> , 2000 , 131, 203-12	8.6	57
2	Corneal kindling in mice: behavioral and pharmacological differences to conventional kindling. <i>Epilepsy Research</i> , 1999 , 37, 109-20	3	35
1	Electrical but not chemical kindling increases sensitivity to some phencyclidine-like behavioral effects induced by the competitive NMDA receptor antagonist D-CPPene in rats. <i>European Journal of Pharmacology</i> , 1998 , 353, 177-89	5.3	10